Navigation Links
ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors
Date:1/3/2012

EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Julie H. McHugh to its board of directors.

Ms. McHugh brings a wealth of pharmaceutical and health care industry experience and leadership to ViroPharma's Board of Directors.  She is currently the chief operating officer of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  Prior to joining Endo, Ms. McHugh was chief executive officer of Nora Therapeutics, Inc., a biotech company focused on the treatment of infertility disorders.  Prior to joining Nora Therapeutics, she was company group chairman for Johnson & Johnson's Worldwide Virology Business Unit and prior to this role she served as president of Centocor, Inc., a J&J subsidiary.

Ms. McHugh received a Bachelor of Science degree from Pennsylvania State University and a Masters of Business Administration degree from St. Joseph's University.  She currently serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University.  Ms McHugh also currently serves on the Board of Directors of Biotechnology Industry Association (BIO), New England Health Institute (NEHI) and the Nathaniel Adamczyk Foundation.  Ms. McHugh served in 2009 as Chairman of the Board of Directors for the Pennsylvania Biotech Association.

"We are very enthusiastic about the addition of Julie to our board," commented Vincent Milano, president and chief executive officer of ViroPharma.  "Julie's experience and insight gained from years of pharmaceutical leadership at a number of successful organizations will play a critical role in helping guide our company through our next levels of growth and achievement." 

"I am excited to have the opportunity to serve on the board of directors of ViroPharma; I am impressed by the success that the company has achieved and look forward to taking part in guiding the company towards future growth and successes in the years ahead," commented Ms. McHugh.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, adrenal insufficiency, and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

 


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma
2. ViroPharma Announces Approval of Modernized Labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules
3. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
4. ViroPharma to Participate in Two November Healthcare Investor Conferences
5. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
6. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
7. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. ViroPharma Announces Additional Securities Repurchase Program
10. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
11. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, Florida ... eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen ... der Verkauf ihrer bestehenden Produkte im Tausch gegen ... Zahlung an 3B leisten, um das in ...
(Date:1/22/2017)... Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and delivery ... data and powered by artificial intelligence and this trend is going to get ... of the Future, at the concluding day of the 47 th Annual ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, President of ... a healthcare industry expert at the 2017 Sector Summit hosted by Ivy Tech ... Business host Gerry Dick, will feature an employer and an association representative from ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Old School Labs™, ... added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ... a bodybuilder in 2012 and in less than a year was able to turn ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in ... seafood-rich diet. These resources have been developed for use by nutrition educators ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of tools ... to another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... scene. Easily create the illusion of a DSLR racking focus from one area into ...
Breaking Medicine News(10 mins):